Preliminary pre-clinical results

PLL THERAPEUTICS

Restore intestinal epithelium barrier.

In Trans Epithelial Electric Resistance in vitro model, PLL-001 accelerates intestinal barrier maturation (dose dependant).

Reduces neurodegeneration and muscle waste.

In SOD1 mice models, PLL-001 reduced neurodegeneration and muscle cell apoptosis (microscopy) and improved motor capabilities.

Restores healthy microbiota.

In SOD1 mice models, PLL001 reverted the microbiota observed in sick mouse to the microbiota observed in wild type mice.

Shows no toxicity.

In SOD1 mice models, PLL001 showed not toxicity at the predicted therapeutic dose.